Treatment of resistance to Sacituzumab govitecan

In a large clinical trial, patients with metastatic triple-negative breast cancer (TNBC) who received the compound sacituzumab govitecan lived nearly twice as long as those who received chemotherapy alone. Gosatuzumab is an antibody-drug conjugate (ADC) consisting of an antibody that targets a receptor called Trop2 found on the surface of most breast cancer cells, plus a cancer-killing compound called SN-38 (a topoisomerase I inhibitor). Some patients with metastatic TNBC either do not benefit from gosatuzumab treatment or initially respond to treatment but subsequently develop drug-resistant disease.

The mechanisms of resistance to gosatuzumab vary from person to person, so it is important to understand the patient's specific situation to develop an individualized treatment plan. Doctors may use genetic testing and analysis to determine resistance mechanisms and select appropriate treatments. Combining gosatuzumab with other anticancer drugs may increase the effectiveness of treatment. Different chemotherapy drugs or targeted therapies may be tried in the hope of achieving a better treatment response. Participation in relevant clinical trials can provide patients with access to new treatment options. These trials often include testing of new drugs and evaluation of new treatment strategies.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.